Press

Press

2026-05-04 14:23 Acarix Changes Publication Date for Q1 2026 Interim Report Regulatory
Acarix (ticker: Acarix) hereby announces that the company is postponing the release of its interim report for the first quarter of 2026.
2026-05-04 14:23 Acarix ändrar datum för publicering av delårsrapport för Q1 2026 Regulatory
Acarix (ticker: Acarix) meddelar härmed att bolaget flyttar fram publiceringstidpunkten för delårsrapporten för det första kvartalet 2026.
2026-04-15 13:00 Acarix AB’s Årsredovisning 2025 Regulatory
Acarix, ledande inom AI och avancerad akustikbaserad hjärtdiagnostik, meddelar idag att årsredovisning för 2025 finns tillgänglig som pdf på bolagets...
2026-04-15 13:00 Acarix AB’s Annual Report 2025 Regulatory
Acarix, a global leader in AI and advanced acoustic-based cardiac diagnostics, today announces that the Annual Report for 2025 is available as a pdf on...
2026-04-07 13:00 ACARIX PRESENTS ABSTRACT AT ACC.26 HIGHLIGHTING CADSCOR® SYSTEM'S DIAGNOSTIC UTILITY COMPARED TO STANDARD STRESS TESTS IN CHEST PAIN PATIENTS
Findings demonstrate high NPV, care time savings of up to 40 hours, and cost reductions exceeding $100,000 per inpatient case, reinforcing the commercial...
2026-02-12 08:00 Acarix Publishes Year-End Report 2025 Regulatory
Malmö, Sweden – Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its 2025 year-end financial results. “Last year...
2026-02-11 09:20 Acarix Announces New Distribution Partner in Saudi Arabia for the CADScor System
Malmö, Sweden – Acarix AB (Nasdaq Stockholm: ACARIX), a medical device company advancing noninvasive, AI enabled diagnostics for coronary artery disease...
2026-02-04 09:20 Acarix Receives EU MDR Certification for the CADScor®System
Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announced that its CADScor System has successfully achieved...
2025-12-08 08:47 ACARIX CARRIES OUT A DIRECTED SHARE ISSUE OF APPROX. SEK 33.4 MILLION Regulatory MAR
The Board of Directors of Acarix AB (publ) ("Acarix" or the "Company") has today resolved to carry out a directed share issue of maximum 117,236,844 shares...
2025-12-08 08:47 ACARIX GENOMFÖR EN RIKTAD EMISSION OM CIRKA 33,4 MSEK Regulatory MAR
Styrelsen i Acarix AB (publ) (”Acarix” eller ”Bolaget”) har idag beslutat om att genomföra en riktad nyemission av högst 117 236 844 aktier till...
2025-11-06 08:45 Invitation to presentation of Acarix´s third quarter 2025 report
Acarix third quarter result is now released and we invite investors, analysts, and media representatives to join the recorded webcast presentation of the...
2025-11-06 08:00 Acarix AB (publ) publicerar tredje kvartalet 2025 Regulatory
Malmö, – Acarix, ledande inom akustisk- och algoritmbaserad hjärtdiagnostik, redovisade idag sina finansiella resultat för det tredje kvartalet 2025...
2025-11-06 08:00 Acarix Publishes Interim Report, Third quarter 2025 Regulatory
Malmö, Sweden – Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the third quarter...
2025-10-27 15:35 Announcement from the general meeting in Acarix AB Regulatory
The extraordinary general meeting 2025 (the "EGM") of Acarix AB ("Acarix" or the "Company") was held today on 27 October 2025 and the following resolutions...
2025-10-27 15:35 Kommuniké från extra bolagsstämma i Acarix AB Regulatory
Extra bolagsstämma i Acarix AB ("Acarix" eller "Bolaget") hölls idag den 27 oktober 2025 varvid aktieägarna fattade besluten nedan.
2025-10-24 15:15 Acarix AB byter Certified Adviser till Tapper Partners AB Regulatory
Malmö – Acarix, ledande inom akustisk- och algoritmbaserad hjärtdiagnostik, meddelar idag att bolaget byter Certified Adviser till Tapper Partners...
2025-10-24 15:15 Acarix AB changes Certified Adviser to Tapper Partners AB Regulatory
Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announce that the company is changing its Certified Adviser...
2025-10-17 08:30 Acarix responds to G-BA decision on reimbursement in the German market
Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announce that G-BA reached a negative decision on the...
2025-10-09 12:15 KALLELSE TILL EXTRA BOLAGSSTÄMMA I ACARIX AB Regulatory
Aktieägarna i Acarix AB, org.nr 559009-0667 (”Bolaget”) kallas härmed till extra bolagsstämma måndagen den 27 oktober 2025 kl. 11.30 i Advokatfirman...
2025-10-09 12:15 NOTICE OF EXTRAORDINARY GENERAL MEETING IN ACARIX AB Regulatory
The shareholders in Acarix AB (publ) corp. reg. no 559009-0667 (the “Company”) are hereby convened to an extraordinary general meeting on Monday 27...
2025-10-07 09:31 Acarix CADScor® System Gains HealthChoice Reimbursement Coverage
Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that HealthChoice, a self-funded insurance...
2025-09-18 17:04 Acarix Chairman Jan Poulsen Acquires Shares
I the period 15. – 18. September, Jan Poulsen privately purchased 475,000 shares at an average price of SEK 0.3053.
2025-09-08 09:45 CEO purchases shares in Acarix
Acarix, a leader in AI-driven and acoustics-based cardiac diagnostics, has announced that its President and CEO, Aamir Mahmood, has increased his investment...
2025-08-21 08:30 Acarix Reports Significant Progress Toward Fixed Reimbursement
Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that the company has achieved another...
2025-08-21 08:00 Acarix Publishes Interim Report, January – June 2025 Regulatory
Malmö, Sweden (Aug. 21, 2025) – Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results...
2025-08-20 09:45 Acarix and Aalborg University Abstract Accepted for AHA 2025
Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that our abstract on the Heart Failure...
2025-08-18 11:09 Invitation to presentation of Acarix´s second quarter 2025 report
Acarix invites investors, analysts, and media representatives to join a recorded webcast presentation of the second quarter report for 2025, scheduled...
2025-07-28 09:47 Acarix achieves new Fixed U.S. reimbursement milestone for CADScor at $300.00 USD
Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that a second payer has agreed to provide...
2025-07-08 16:05 Acarix Enters MENA Region with First Major Order, Expanding Global Presence Regulatory MAR
Malmö, Sweden – July 8, 2025 – Acarix, a global pioneer in AI-driven and acoustics-based cardiac diagnostics, is proud to announce its first order...
2025-06-26 09:40 Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor® System in U.S. Emergency Departments
Malmö, Sweden - Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new peer-reviewed study in PharmacoEconomics...
Next

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.

The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing stable chest pain with suspected CAD and is designed to help reduce millions of unnecessary and costly diagnostic procedures.2 CADScor®System calculates a patient-specific CAD-score non-invasively in 10 minutes with at least 96% confidence (Negative Predictive Value).¹

Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Learn more
  1. User manual US-FDA v.12.Y, prevalence 10,7%
  2. Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.